Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shahram Bahmanyar

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Eclinicalmedicine|November 12, 2019
Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for RomiplostimChristian Fynbo Christiansen, Shahram Bahmanyar, Waleed Ghanima, et al.
British Journal of Haematology|August 13, 2021
Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort studyMargaux Lafaurie, Julien Maquet, Bérangère Baricault, et al.
Multiple Sclerosis and Related Disorders|January 11, 2021
Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn characteristics in a register-based cohort study in Finland and SwedenMarta Korjagina, Katja M Hakkarainen, Sarah Burkill, et al.
Plos One|December 31, 2019
The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosisSarah Burkill, Pia Vattulainen, Yvonne Geissbuehler, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 5, 2008
Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitisAnnika Bergquist, Scott M Montgomery, Shahram Bahmanyar, et al.
Therapeutic Advances in Neurological Disorders|October 26, 2020
Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and SwedenKatja Marja Hakkarainen, Rosa Juuti, Sarah Burkill, et al.
Plos One|September 28, 2018
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United KingdomAndrea V Margulis, Marie Linder, Alejandro Arana, et al.
Current Medical Research and Opinion|February 16, 2021
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladderKelesitse Phiri, Jesper Hallas, Marie Linder, et al.
Clinical Pharmacology and Therapeutics|August 20, 2021
Lessons Learned Using Real-World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune ThrombocytopeniaLeah J McGrath, Carrie Nielson, Bradley Saul, et al.
Pharmacoepidemiology and Drug Safety|January 11, 2021
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United StatesVera Ehrenstein, Kui Huang, Johnny Kahlert, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Eclinicalmedicine|November 12, 2019
Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for RomiplostimChristian Fynbo Christiansen, Shahram Bahmanyar, Waleed Ghanima, et al.
British Journal of Haematology|August 13, 2021
Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort studyMargaux Lafaurie, Julien Maquet, Bérangère Baricault, et al.
Multiple Sclerosis and Related Disorders|January 11, 2021
Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn characteristics in a register-based cohort study in Finland and SwedenMarta Korjagina, Katja M Hakkarainen, Sarah Burkill, et al.
Plos One|December 31, 2019
The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosisSarah Burkill, Pia Vattulainen, Yvonne Geissbuehler, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 5, 2008
Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitisAnnika Bergquist, Scott M Montgomery, Shahram Bahmanyar, et al.
Therapeutic Advances in Neurological Disorders|October 26, 2020
Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and SwedenKatja Marja Hakkarainen, Rosa Juuti, Sarah Burkill, et al.
Plos One|September 28, 2018
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United KingdomAndrea V Margulis, Marie Linder, Alejandro Arana, et al.
Current Medical Research and Opinion|February 16, 2021
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladderKelesitse Phiri, Jesper Hallas, Marie Linder, et al.
Clinical Pharmacology and Therapeutics|August 20, 2021
Lessons Learned Using Real-World Data to Emulate Randomized Trials: A Case Study of Treatment Effectiveness for Newly Diagnosed Immune ThrombocytopeniaLeah J McGrath, Carrie Nielson, Bradley Saul, et al.
Pharmacoepidemiology and Drug Safety|January 11, 2021
Outcomes in patients with lung cancer treated with crizotinib and erlotinib in routine clinical practice: A post-authorization safety cohort study conducted in Europe and in the United StatesVera Ehrenstein, Kui Huang, Johnny Kahlert, et al.
Pageof 9